Thursday 16 October, 2025
Context: Group comparaison methods for Non-linear mixed effects models (NLMEM) enable to identify parameters whose estimations significantly vary across the…
Read moreOral: Stuart Beal Methodology Session
Simulated model based adaptive optimal design of adult to children bridging study using FDA stopping criteria.
Thursday 16 October, 2025
Objectives: In traditional design, the size of the study population is regularly calculated a priori using power calculations which are dependent…
Read morePrediction of pharmacokinetic interactions for drugs with a long half-life – evidence for the need of model-based analysis
Thursday 16 October, 2025
Objectives: DDI studies are commonly performed as single-dose crossover studies where AUC and Cmax w/wo perpetrator drug are compared [1,2]. The…
Read moreAveraged Model Based Decision Making for Dose Selection Studies
Thursday 16 October, 2025
Objective: Approximately one third of the cost of a drug development program incurs in Phase III clinical studies, hence the correctness…
Read morePreconditioning of Nonlinear Mixed Effect models for Stabilization of the Covariance Matrix Computation
Thursday 16 October, 2025
Objectives: As the importance of pharmacometric analysis increases, more and more complex models are introduced and computational stability starts to become a bottleneck. We…
Read more